ALBO earnings

Transaction focused on Bylvay® (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases Acquisition aligned with Ipsen's long-term strategy for expanding the scope of its Rare Disease portfolio and pipeline Ipsen to commence cash tender offer to acquire all issued and outstanding shares of Albireo for $42.00 per share plus a contingent value right (CVR) of $10.00 per share related to the U.S. FDA approval of Bylvay in biliary atresia Regulatory News: Ipsen (OTC:IPSEY) and Albireo (NASDAQ:ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acqu

Bylvay® (odevixibat) Q3 2022 PFIC net revenue of $7.5 million, September YTD 2022 $18.1 millionNew disease modification and native liver survival data with Bylvay in PFIC patients presented at AASLD Positive Bylvay Phase 3 ASSERT topline data in ALGS presented at AASLD; submissions on track Completed enrollment in BOLD study in biliary atresia, third Bylvay Phase 3 programCompany to host a conference call and webcast today at 4:30 p.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare disease company developing novel bile acid modulators to treat rare pediatric and adult liver diseases, today provided a business update and reported financial results

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on November 8, 2022, to provide a business update and review the company's financial results for the quarter ended September 30, 2022. To access the live conference call by phone, dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international), and provide the access code 10020423. A live audio webcast will be accessible from the Investors page at ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that partici

Highly statistically significant improvement in pruritus primary endpoint (p=0.002)Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001)Substantial improvements in multiple sleep parametersWell tolerated with low incidence of drug-related diarrhea, no discontinuationsPlans to immediately file in the U.S. and EU, adding to approved indication for PFIC Conference call to be held today at 8:30am EDT BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced positive topline results from the Phase 3 ASSERT study evaluating

Bylvay®(odevixibat) Q2 2022 net product revenue $5.9 million, June YTD 2022 $10.5 millionAgreed Bylvay reimbursement contract in Italy and Belgium with launches planned for the fallGlobal Phase 3 ASSERT study in Alagille syndrome on track for topline data readout this fallGlobal Phase 3 BOLD study in biliary atresia on track for full enrollment in 2022Company to host a conference call and webcast today at 4:30 p.m. ET BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators to treat rare pediatric and adult liver diseases, today provided a business update and reported financial results for the quarter

BOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on August 15, 2022, to provide a business update and review the company's financial results for the quarter ended June 30, 2022. To access the live conference call by phone, dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international), and provide the access code 10019926. A live audio webcast will be accessible from the Investors page at ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that participants re

Positive Bylvay™ (odevixibat) global commercial launch in U.S., Germany and United Kingdom with Q1 2022 product revenue, net $4.7 million Phase 3 ASSERT study in Alagille syndrome fully enrolled, patient numbers above original target and on track for topline data readout in 2022Phase 3 BOLD study in biliary atresia on track for full enrollment in 2022A3907 and A2342 on track for Phase 2 and Phase 1 study starts this yearCompany to host a conference call and webcast today at 4:30 p.m. ET BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today provided a business update and reported financial res

BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on May 16, 2022, to provide a business update and review the company's financial results for the quarter ended March 31, 2022. To access the live conference call by phone, dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13729296. A live audio webcast will be accessible from the Investors page at ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that participants register

Bylvay™ (odevixibat) launched in the U.S. and Europe, 2021 product revenue, net $7 millionNICE endorses clinical and economic benefits of BylvayPhase 3 study in Alagille syndrome on track for readout in 2022Reports $248.1 million of cash and cash equivalents, sufficient to fund operations into 2024Company to host a conference call and webcast today at 10:00 a.m. ET BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021. "The response to Bylvay from healthcare providers, patients

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on March 1, 2022, to provide a business update and review the company's financial results for the fourth quarter and year ended December 31, 2021. To access the live conference call by phone, dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13727211. A live audio webcast will be accessible from the Media & Investors page of Albireo's website ir.albireopharma.com/. To ensure a timely connection to the webcas

– Evidence of long-term clinical treatment benefit of Bylvay™ (odevixibat) showing improved liver health and function across PFIC types – – Data show Bylvay therapy up to 128 weeks, sustained improvements in hepatic health, quality of sleep and growth, reducing disease burden – – First data on A2342, the first oral systemic NTCP inhibitor, shows inhibition of Hepatitis B viral entry and replication in preclinical models – – Company to host post-AASLD call on November 16, 2021 at 10 a.m. ET – BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced new data from the Phase 3 PEDFIC

– Bylvay™ (odevixibat) approved in the U.S. and Europe, partial Q3 '21 revenue of $1.1 million– – ASSERT & BOLD Phase 3 studies enrolling, on track for topline data readouts – – 12 abstracts accepted at AASLD & NASPGHAN scientific congresses – – A3907 Phase 1 topline data expected in Q4'21, A2342 composition of matter allowed – – $120M in additional non-dilutive capital from sale of PRV and partnership agreement in Japan – – Elobixibat royalty revenue of $2.6 million to be passed on to HealthCare Royalty Partners – – Company to host a conference call and webcast today at 10:00 a.m. ET – BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver diseas

BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on November 4, 2021, to provide a business update and review the company's financial results for the third quarter ended September 30, 2021. To access the live conference call by phone, please dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access code 13723976. A live audio webcast will be accessible from the Media & Investors page of Albireo's website, https://ir.albireopharma.com/. To ensure a timely connection to

– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases – – Phase 3 Bylvay™ (odevixibat) data presentations on long-term treatment benefits show evidence of improved liver health and function across PFIC types – – Data presentations on A2342, the first oral systemic sodium-taurocholate co-transporting peptide (NTCP) inhibitor for development in viral and cholestatic liver diseases – – Company to host post-AASLD call on November 16, 2021 at 10 a.m. EST – BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced the presentation of data at the Am

– BylvayTM (odevixibat) approved in U.S. & EU as only once-daily drug indicated for patients with PFIC – – Commercialization underway with Bylvay, first prescriptions received in the U.S. – – German price listing expected in September – – Company to host a conference call and webcast today at 10:00 a.m. ET – BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the second quarter ended June 30, 2021. "Bylvay is now approved in over 30 countries around the world and we are delighted that the first prescriptions for Bylvay have b

– Only once-daily drug indicated for the treatment of pruritus in PFIC – – Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rare Pediatric Disease Priority Review Voucher issued to Albireo by the FDA – – Company to host investor conference call on July 21 at 8:30 a.m. ET – BOSTON, July 20, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a rare liver disease company developing novel bile acid modulators, today announced U.S. Food & Drug Administration (FDA) approval of Bylvay (odevixibat), the first drug approved for the treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC). Bylvay is a potent,